What is the adverse effects of febuxostat and allopurinol and to which patients they are not given and the other drug is used
Reading File
Finding Sources
Finding Sources
Searching the Web
febuxostat vs allopurinol adverse effects contraindications comparison
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Here is the complete answer:
Allopurinol vs Febuxostat: Adverse Effects, Contraindications & When to Switch
Both are xanthine oxidase (XO) inhibitors used for gout and hyperuricemia. They share some overlap in adverse effects but differ importantly in their safety profiles and which patients tolerate each better.
ALLOPURINOL
Adverse Effects
- Hypersensitivity reactions - the most common adverse effects; may appear after months or even years of therapy. Manifestations range from pruritic, erythematous, or maculopapular skin rash to urticarial or purpuric lesions
- Stevens-Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) - rare but potentially fatal. Risk is highest in the first 2 months of therapy. Strongly associated with the HLA-B*5801 allele (higher frequency in Korean, Thai, Han Chinese, and Sardinian Italian populations)
- Allopurinol Hypersensitivity Syndrome (AHS) - systemic reaction including fever, malaise, myalgias, eosinophilia, hepatitis, and renal failure
- Gout flares - paradoxical worsening in the first few months as urate mobilizes from deposits; co-prescribe colchicine or NSAIDs prophylactically
- Leukopenia / leukocytosis / eosinophilia - rare, may require stopping the drug
- Hepatomegaly and elevated liver transaminases
- Fever, malaise, myalgias - in ~3% of patients, more frequent with renal impairment
- Rash with ampicillin co-use - incidence increases significantly
- Drug interaction toxicity - inhibits XO-mediated inactivation of mercaptopurine and azathioprine; if used together, reduce azathioprine/mercaptopurine dose to 25-33% of usual dose to avoid bone marrow suppression
Contraindications / When NOT to Use Allopurinol
| Situation | Reason |
|---|---|
| Prior serious hypersensitivity/AHS/SJS/TEN to allopurinol | Risk of recurrence or fatal reaction |
| Nursing mothers | Drug excreted in breast milk; not safe |
| Children (general) | Contraindicated except those with malignancy or inborn errors of purine metabolism (e.g., Lesch-Nyhan syndrome) |
| HLA-B*5801 positive patients (especially East/Southeast Asian ancestry) | Very high risk of SJS/TEN |
| Concurrent azathioprine or mercaptopurine without dose adjustment | Severe bone marrow toxicity |
In patients with renal impairment, dose reduction is required (dose adjusted to GFR). Risk of AHS is higher in those with CKD, especially on thiazide diuretics.
FEBUXOSTAT
Adverse Effects
- Gout flares - most common complication on initiation; always co-prescribe prophylaxis
- Liver function abnormalities - most common treatment-related adverse event; monitor LFTs periodically
- Nausea, diarrhea, headache, joint pain
- Rash - occurs in <2% and is dose-dependent; less common than with allopurinol
- Hypersensitivity vasculitis of skin - reported post-marketing; rare
- Cardiovascular risk - the CARES trial showed a 20-30% higher risk of all-cause and cardiovascular mortality vs allopurinol in patients with pre-existing cardiovascular disease; however, the larger European FAST trial (with only 5.8% dropout) found NO difference. The FDA issued a boxed warning for possible increased risk of cardiovascular death. The FAST trial has since prompted experts to re-evaluate this warning
- Drug interaction - azathioprine/mercaptopurine: Febuxostat inhibits XO and raises plasma levels of these agents - contraindicated combination
Contraindications / When NOT to Use Febuxostat
| Situation | Reason |
|---|---|
| Patients on azathioprine or mercaptopurine | Severe drug interaction - toxic accumulation |
| Patients with established cardiovascular disease / high CV risk (relative) | FDA boxed warning for increased CV mortality (based on CARES trial) |
| Severe renal impairment (stage 4-5 CKD) | No safety data; use with caution or avoid |
The Key Clinical Trade-off: When to Choose One Over the Other
| Patient Profile | Preferred Drug |
|---|---|
| Allopurinol intolerance / allergy / AHS / SJS | Use febuxostat - structurally unrelated, less risk of cross-reaction (12/13 patients tolerated it safely in retrospective studies) |
| Moderate CKD (Stage 1-3, CrCl 30-90 mL/min) | Use febuxostat - not renally cleared to the same degree; does not need the same dose adjustments as allopurinol |
| Severe CKD (Stage 4-5) | Use allopurinol with dose reduction - febuxostat has no safety data here |
| HLA-B*5801 positive | Use febuxostat - avoids the genetic risk of SJS/TEN with allopurinol |
| Patients on azathioprine or mercaptopurine | Neither drug alone is ideal; allopurinol CAN be used with a mandatory 75% dose reduction of the immunosuppressant; febuxostat is contraindicated |
| Established cardiovascular disease | Prefer allopurinol - fewer CV mortality concerns; if febuxostat must be used, monitor closely |
| General first-line gout management | Allopurinol is preferred over febuxostat and probenecid as first-line urate-lowering therapy |
| Allopurinol failure (didn't reach target uric acid) | Consider febuxostat at 80 mg - more patients reach target <6 mg/dL vs allopurinol 300 mg/day |
Key Summary:
- Allopurinol is first-line; febuxostat is primarily used when allopurinol is contraindicated, not tolerated, or ineffective
- Febuxostat has less renal elimination - safer in mild-moderate CKD without dose adjustment
- Febuxostat has a lower risk of skin hypersensitivity than allopurinol
- Neither should be combined with azathioprine or mercaptopurine without caution; febuxostat is outright contraindicated with these agents
- Both require gout flare prophylaxis at initiation
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | Lippincott Illustrated Reviews Pharmacology | Katzung's Basic and Clinical Pharmacology 16e | Firestein & Kelley's Textbook of Rheumatology
This is a shared conversation. Sign in to Orris to start your own chat.